Home > Journals > Minerva Pneumologica > Past Issues > Minerva Pneumologica 2004 December;43(4) > Minerva Pneumologica 2004 December;43(4):183-8





A Journal on Diseases of the Respiratory System

Official Journal of the Italian Society of Thoracic Endoscopy
Indexed/Abstracted in: EMBASE, Scopus, Emerging Sources Citation Index




Minerva Pneumologica 2004 December;43(4):183-8

Intravenous (iv) azithromycin (AZM)/ ceftriaxone followed by po AZM versus iv lefofloxacin (LEV) followed by po LEV in treatment of hospitalized patients with community-acquired pneumonia

Zervos M., Andrews C., Amsden G., Knirsch C., Swanson R., De Caprariis P., Mandell L.


Aim. Treatment options for hospitalized community-acquired pneumonia (CAP) patients include a ß-lactam/macrolide combination or monotherapy with an antipneumococcal fluoroquinolone. We compared clinical efficacy/safety of sequential therapy with intravenous (IV) azithromycin (AZM; 500 mg qd)/ceftriazone (CEF; 1 g qd) followed by PO AZM (500 mg qd) versus IV levofloxacin (LEV 500 mg qd) followed by PO LEV (500 mg qd) in patients with moderate/severe CAP.
Methods. This was a randomized, multicenter, open-label study. Length of therapy: AZM/CEF was 7 to 10 days and LEV 7 to 14 days. Clinical and bacteriological outcomes were assessed on Day 12-16, end of treatment (EOT), and on Day 28-35, end of study (EOS).
Results. One hundred ten and 102 patients were treated with AZM/CEF and LEV, respectively. Hospital length of stay was 8.3 days versus 8.6 days, respectively. Majority of patients were in risk classes III/IV (Fine Pneumonia Severity Index); mean risk index was similar (97.7 for AZM/CEF; 97.8 for LEV). Mean age was 70.7 years in AZM/CEF group and 72.8 years in LEV group. In the clinically evaluable analysis, clinical success rates (cure or improvement) at EOT were 91.5% for AZM/CEF and 89.3% for LEV. EOS success rates (cure only) were 89.2% for AZM/CEF versus 85.1% for LEV (95% CI: ­6.7%, 14.8%). Response rates for the most frequently isolated pathogens were similar in both groups. Incidence of treatment related adverse events was comparable.
Conclusion. Intravenous AZM/CEF followed by PO AZM was comparable in efficacy and safety to IV LEV followed by PO LEV in treating hospitalized patients with CAP.

top of page

Publication History

Cite this article as

Corresponding author e-mail